Almost a decade after the purchase of Zentiva BV, Sanofi has now finished negotiations with the private equity firm Advent International for the €1.9bn sale of its European generics business, as the French drugmaker continues to reshape its operations and focus on its newer purchases Bioverativ Inc. and Ablynx NV.
Sanofi and Advent have now signed a share purchase agreement for the sale of Zentiva, having announced April 17 that they had entered into exclusive talks
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?